Loading clinical trials...
Loading clinical trials...
Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HM61713 in NSCLC Patients With EGFR Mutation
Conditions
Interventions
HM61713
Locations
1
South Korea
Seoul, South Korea
Start Date
March 1, 2012
Primary Completion Date
August 1, 2017
Completion Date
August 1, 2017
Last Updated
April 24, 2018
NCT06066138
NCT07485114
NCT05098132
NCT06284317
NCT06731413
NCT06687369
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions